Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACKR3 | P25106 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.43 |
| ▸ | TCF4 | P15884 | 1/20 | 0.42 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7571867 | 0.92 | ACKR3 (0.50) | ACKR3MEN1KMT2APOLBDEGS1 | |
| SCHEMBL8202126 | 0.92 | ACKR3 (0.50) | ACKR3MEN1KMT2APOLBDEGS1 | |
| SCHEMBL13081821 | 0.82 | CNR1 (0.44) | MEN1KMT2APOLBCNR1TDP1 | |
| SCHEMBL7569678 | 0.81 | DEGS1 (0.49) | MEN1KMT2ADEGS1SMN1; SMN2NPC1 | |
| SCHEMBL13054426 | 0.81 | DEGS1 (0.49) | MEN1KMT2ADEGS1SMN1; SMN2NPC1 | |
| SCHEMBL7566088 | 0.77 | ACKR3 (0.46) | ACKR3MEN1KMT2APOLBSMN1; SMN2 | |
| SCHEMBL17270266 | 0.76 | ACKR3 (0.75) | ACKR3DEGS1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL7603617 | 0.76 | SMN1; SMN2 (0.50) | ACKR3MEN1KMT2APOLBSMN1; SMN2 | |
| SCHEMBL7565087 | 0.75 | ACKR3 (0.50) | ACKR3MEN1KMT2APOLBSMN1; SMN2 | |
| SCHEMBL8112685 | 0.72 | CNR1 (0.61) | KMT2APOLBCNR1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100292203-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | SCHERING CORPORATION | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292203-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | CHRM1, CHRM2, PRSS1 | ACKR3 1259/4885MEN1 1192/4885KMT2A 4458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.